Podcasts about Bruton

Featuring an interview with Dr Lindsey Roeker, including the following topics: Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00) Safety of BTK inhibitors in older and frail patients with CLL (3:41) Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20) Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32) Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31) Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16) Sequencing, tolerability and future development involving pirtobrutinib (25:57) Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28) Clinical considerations in the management of Richter's transformation (38:14) Survival outcomes and quality of life for patients with CLL (41:02) Ongoing and future efforts to improve CLL treatment outcomes (45:01) CME information and select publications  

Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics: Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00) Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax  (7:03) Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35) Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28) Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease  (15:52) Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12) Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor  (19:38) Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment  (22:15) Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13) Available data with epcoritamab monotherapy for R/R CLL  (26:58) The emerging pharmacologic class of BTK degraders  (29:04) CME information and select publications

A host of exhibitions and events this month and next celebrate the 100th anniversary of the birth of the Swiss artist Jean Tinguely, one of the godfathers of kinetic and auto-destructive art. Ben Luke speaks to Roland Wetzel, the director of the Tinguely Museum in Basel about the artist's life and work, and the events marking the centenary. In Rotterdam in the Netherlands, Fenix, a museum about migration, has just opened, featuring a dramatic stainless steel tornado form on its roof. We discuss the museum with its director, Anne Kremers. And this episode's Work of the Week is by an immigrant artist, Ben Shahn, who was born in modern-day Lithuania but travelled as a child to the US, where he became a leading painter associated with Social Realism. Among his greatest achievements was the mural The Meaning of Social Security, painted between 1940 and 1942 in Washington D.C. to reflect the benefits of the then-recent Social Security Act. Shahn is the subject of a major show that opened this week at the Jewish Museum in New York. We speak to Laura Katzman, the co-curator of the exhibition with the Jewish Museum's Stephen Brown, about Harvesting Wheat (1941), Shahn's study for one of the figures in the mural.The Tinguely Museum in Basel, Switzerland, has a permanent display of his work; Scream Machines–Art Ghost Train, by Rebecca Moss and Augustin Rebetez, Tinguely Museum, until 30 August; Mechanics and Humanity: Eva Aeppli and Jean Tinguely, Lehmbruck Museum, Duisburg, Germany, until 24 August; Niki de Saint Phalle & Jean Tinguely: Myths & Machines, Hauser & Wirth Somerset, Bruton, UK, until 1 February 2026; Niki de Saint Phalle, Jean Tinguely, Pontus Hultén, Grand Palais, Paris, 20 June-4 January 2026.The Fenix museum is open now.Ben Shahn: On Nonconformity, Jewish Museum, New York, 23 May-12 October. The book accompanying it published on 3 June by Princeton University Press, priced $45.00/£38.00.The Meaning of Social Security murals:https://art.gsa.gov/artworks/637/the-meaning-of-social-security?ctx=3bc918796c456cc8fb8e3d3f033918d4249d0ce6&idx=6https://livingnewdeal.org/sites/wilbur-j-cohen-building-shahn-frescoes-washington-dc/#lg=1&slide=1 Hosted on Acast. See acast.com/privacy for more information.

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

Bryan Bruton shares his insane life story! Bryan's Links https://www.youtube.com/@UC_S8-o7r0W979pS8j_7snPw https://www.instagram.com/bryanbruton_/https://www.facebook.com/bryan.bruton.2025/Go to https://ground.news/Inside for abetter way to stay informed. Subscribe for 40% off unlimited access to world-wide coverage through my link.Do you want to be a guest? Fill out the form https://forms.gle/5H7FnhvMHKtUnq7k7Send me an email here: insidetruecrime@gmail.comDo you extra clips and behind the scenes content?Subscribe to my Patreon: https://patreon.com/InsideTrueCrime

On this episode of The Claw's Corner Rich "The Claw" Cyr has a great conversation with the Raizine Bruton of Best Video! They chat all things film and video and so much more! Visit Best Video! 1842 Whitney Avenue, Hamden, CT 06517 Find Best Video online: https://www.bestvideo.com/  / bestvideohamden   https://bestvideo.creator-spring.com/ Do not miss Rich's book, "Confessions of a Frenetic Mind" available now - https://www.amazon.com/Confessions-Fr... Copyright 2025 The Claw's Corner - Produced by Rich Cyr  / richtheclawcyr   Edited by Elmwood Productions - http://elmwoodproductions.com/index.html and subscribe to Elmwood Productions on YouTube:    / elmwoodproductions   Show some love for Elmwood! It's your support that keeps content like this coming! Join our Patreon now!  / elmwoodproductions  

Partners in life and work, Jules and Steve Horell bought an old cow barn in Somerset, built a fire kitchen and started running dining experiences which they launched under the name Horrell & Horrell in 2023. I met Jules and Steve when I first moved to Bruton when he was the head chef and she was front of house at the Roth Bar & grill - the restaurant at Hauser & Wirth. Having worked in the hospitality industry for 20 years they've seen food trends come and go, climate's change and people move in & out of the area. When they decided to set they're own thing up, they were able to come up with a concept that was true to them; Friendly, delicious and homely. And they make it all happen so effortlessly! I sat down with Jules in their home kitchen and chat about how it all started. Welcome to the podcast Jules Horrell. Hosted on Acast. See acast.com/privacy for more information.

For The Other Side NDE Videos Visit ▶️ youtube.com/@TheOtherSideNDEYT Today, a skilled pilot shares the gripping story of his near-death experience following a plane crash that should have claimed his life. In the moments beyond consciousness, he entered a space where time and reality blurred, encountering a presence that offered him a choice—to move on or return. Faced with this life-altering decision, he gained powerful insights into the interconnectedness of fate, free will, and the unseen guidance shaping our lives. ⭐ Check Out More Of Jim's Near Death Experience NDE On His Website

Summary of Criminal Procedure – Lecture 3 Introduction Lecture 3 focuses on constitutional protections in criminal proceedings, covering the Fifth and Sixth Amendments and pretrial and trial procedures. Key Topics: Fifth Amendment: Protection against self-incrimination, Miranda warnings, and double jeopardy. Sixth Amendment: Right to counsel, a speedy trial, an impartial jury, and confrontation of witnesses. Pretrial & Trial Procedures: Grand juries, bail, plea bargaining, discovery, burden of proof, sentencing, and post-conviction relief. I. The Fifth Amendment Protects individuals from coerced confessions and multiple prosecutions. A. Miranda Rights & Custodial Interrogation Miranda v. Arizona (1966): Suspects must be informed of right to remain silent and counsel. Failure to provide warnings may make confessions inadmissible. Exceptions: Public safety, spontaneous statements, and routine booking questions. B. Voluntary Confessions & Self-Incrimination Confessions must be voluntary—coercion makes them inadmissible. Exclusionary rule bars evidence obtained in violation of Miranda. Privilege against self-incrimination applies only to testimonial evidence. C. Double Jeopardy Prohibits multiple prosecutions or punishments for the same offense. Exceptions: Separate sovereigns doctrine, mistrials, and appeals. II. The Sixth Amendment Guarantees fair trial rights. A. Right to Counsel Gideon v. Wainwright (1963): Indigent defendants must be provided counsel. Applies at all critical stages, including plea negotiations and sentencing. Strickland v. Washington (1984): Defendants may claim ineffective assistance of counsel. B. Speedy & Public Trial Barker v. Wingo factors: Length, reason, defendant's assertion, and prejudice. Speedy Trial Act (1974): Federal trials must start within 70 days. C. Impartial Jury Batson v. Kentucky (1986): Prohibits racial discrimination in jury selection. Ramos v. Louisiana (2020): Criminal convictions require unanimous verdicts. D. Confrontation Clause Right to cross-examine witnesses. Bruton v. United States (1968): Co-defendant's confession cannot be used against another defendant. Maryland v. Craig (1990): Limited exceptions for child victims. III. Pretrial & Trial Procedures Focuses on probable cause, bail, plea deals, burden of proof, and sentencing. A. Grand Juries & Bail Grand juries determine probable cause, but defendants cannot present evidence. Bail must not be excessive (8th Amendment); based on flight risk, crime severity, and public safety. B. Plea Bargains & Discovery Most cases resolve through plea deals. Brady v. Maryland (1963): Prosecution must disclose exculpatory evidence. C. Burden of Proof at Trial Prosecution must prove guilt beyond a reasonable doubt. Direct vs. Circumstantial Evidence: Direct = witnesses, videos; Circumstantial = motive, behavior. D. Sentencing & Post-Conviction Relief Mandatory minimums limit judicial discretion. Death penalty restrictions: Roper v. Simmons (2005) bars execution of juveniles. Appeals & Habeas Corpus: Review constitutional errors. Wrongful Convictions: DNA evidence & Innocence Project help exonerate the falsely accused. Conclusion Today covered constitutional protections, trial rights, and post-conviction remedies. These safeguards ensure fairness, prevent wrongful convictions, and protect due process. Tomorrow, we will examine criminal appeals and habeas corpus petitions.

Forward and Hull-born #11 Owen Bruton joins the pod after signing a new two-year extension to stay at the Seahawks

"In B cell malignancies, BTKi inhibits that BTK enzyme which is very upstream. It tells NF-κB to stop signaling into the nucleus and then inhibits proliferation and survival of B cells."  Puja Patel, PharmD, BCOP, Clinical Oncology Pharmacist at Northwestern Medicine Cancer Center at Delnor Hospital in Geneva, IL, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about BTK inhibitors.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 1.0 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 17, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learners will report an increase in knowledge related to the BTK inhibitor drug class.  Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ Pharmacology 101 series  ONS Voice articles:  BTK Inhibitor Effective for Relapsed Hairy Cell Leukemia  FDA Grants Accelerated Approval to Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma  Ibrutinib Is the First Anticancer Agent to Be Negotiated for Medicare Drug Pricing  Oncology Drug Reference Sheet: Pirtobrutinib  Oncology Drug Reference Sheet: Zanubrutinib  ONS books:  Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition)  Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition)  Clinical Journal of Oncology Nursing article: B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management  ONS courses:   ONS Cancer Biology™  ONS/ONCC Chemotherapy Immunotherapy Certificate™   Safe Handling Basics   ONS Guidelines™ and Symptom Interventions:   Chemotherapy-Induced Diarrhea  Prevention of Bleeding  Prevention of Infection: General  ONS Learning Library: Oral Anticancer Medication  ONS/NCODA/HOPA/ACCC's Oral Chemotherapy Education Sheets  Other resources:  Advanced Practice Providers Oncology Summit  Ash Publications article: Managing Toxicities of Bruton Tyrosine Kinase Inhibitors  Blood Advances article: BTK Inhibitors in CLL: Second-Generation Drugs and Beyond  CLL Society Fact Sheets  International Journal of Molecular Sciences article: Bruton's Tyrosine Kinase Inhibitors: Recent Updates  National Cancer Institute article: Two Drugs Show Efficacy against Common Form of Leukemia  National Comprehensive Cancer Network Guidelines for Patients: Chronic Lymphocytic Leukemia  National Study of Lymphoma (University of Oxford network site-specific group— Hematology)  NCODA's Positive Quality Intervention resources  Pharmacy Times BTK Inhibitor Comparison Charts  ScienceDirect article: Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse  The Video Journal of Hematology and Hematological Oncology  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.    Highlights From This Episode  “1952 we have the discovery by Colonel Ogden Bruton of that severe immunodeficiency due to lack of B-cell maturation, and next linked to e-gamma globular anemia. In 1993, we had Professor Vetrie and colleagues discover that this was actually due to mutation in a kinase, and they called that BTK. And then in 1993 was a discovery of our first BTKi inhibitor in the lab setting, and that's called LFM-A13. It wasn't until 2013, so that's 20 years after BTK kinase was discovered, where ibrutinib was our first-in-class BTK inhibitor, and the success of ibrutinib really promoted the exploration of second- and third-generation BTKis.” TS 6:24     “It's thought that BTK and other members in the pathway are constitutively phosphorylated, which just means they're spontaneously on. This leads to this uncontrolled activation of NF- κB signaling and thus uncontrolled proliferation and suppression of apoptosis. So, these B cells are rapidly dividing, but they're not functioning like they're supposed to be, meaning they won't differentiate, or, you know, they won't grow up to be either a plasma cell, like we talked about, or a memory B cell. They've been hacked.” TS 10:11     “This class is generally called—if you have to think of an umbrella term—it's just called targeted small molecule therapies. Now a subclass is BTKi or Bruton tyrosine kinase inhibitors. So, we're really shifting away from the use of cytotoxic chemotherapy, which is kind of designed to indiscriminately destroy rapidly dividing cells, to a more precise approach of targeting cells based on specific molecular changes in tumor DNA.” TS 13:47     “Cardiac toxicity can manifest as atrial fibrillation. And here I'll specifically talk about ibrutinib values because we have the most data with it, and the numbers actually get better with second- and third-generation BTKis. So frequency: Grade 1–2 atrial fibrillation was reported in 12%–15% of patients on Ibrutinib. And grade 3 AFib is 3%–5%. The onset, median onset is 8–13 months.” TS 20:23     “For nurses, they should really advise their patients that the caliber of headaches are easily managed and they will decrease over time over a period of four weeks. This is an upfront conversation reassuring the patient that this is not a long-term side effect.” TS 33:47     “One aspect that was being discussed at length was kind of identifying biases and then methods to neutralize those biases. So, I think first you have to identify what your bias could be toward BTK, maybe it's age or comorbidities or side-effect profile. And then, how can we mitigate our own biases is kind of the solution part to that.” TS 46:26 

Back with my first episode of 2025 talking college football playoffs with Dylan Bruton, giving you my 2025 NBA MVP ladder, and reflecting on 2024.

Unionists fiercely resist calls for a border poll for on a United Ireland, but that was not always the case. David Trimble campaigned for a poll in 2002 – secret files reveal he was dismissed. Newly released Dublin files reveal former taoiseach John Bruton was suspicious not only of Sinn Féin and the SDLP, but even his own Department of Foreign Affairs. Other files reveal a young John F Kennedy was happy enough with partition of Ireland and how Roger Casement was a source of controversy long after his execution. Ralph Reigel from the Irish Independent joins Ciarán Dunbar. Hosted on Acast. See acast.com/privacy for more information.

Today we are bringing you a conversation on treatment with Bruton tyrosine kinase inhibitors for patients with treatment-naïve chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Ryan Haumschild, PharmD, MS, MBA, CPEL, vice president of ambulatory pharmacy at Emory Healthcare and Winship Cancer Institute, spoke with 3 experts: Tara Graff, DO, medical oncologist, Mission Cancer and Blood; Jacqueline Barrientos, MD, MS, chief, Hematologic Malignancies, and director, Oncology Research at Mount Sinai Comprehensive Cancer Center; and Matthew Davids, MD, MMSc, director of Clinical Research, Division of Lymphoma, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School. They covered a wide range of topics including the data on treatment regimens for both CLL and MCL, the cost of treatment, patient-specific considerations during treatment decision making, and the future of treatment.

NBL NOW | Everything NBL Cal Bruton & Jack Heverin The great Cal Bruton talks World Basketball Day with Jack HeverinSee omnystudio.com/listener for privacy information.

This is the last episode of series 3. I have absolutely loved chatting to all the guests and feel very grateful for having met such inspiring people. Today's conversation is with Rosanna Philpott, founder of Pygmalion, a dinner candle company launched in August of this year. Lighting a tall dinner candle in anticipation for the arrival of guests, really is the moment before the fun is about to commence. Rosanna has developed candles that capture this magic with designs that are modern, fun and look great placed on any table or mantle.Rosanna and I chat through the story behind the name Pygmalion and how her painting and travels to Kenya have inspired the candle designs. I hear about how hard it was finding her factory and the disasters she's had along the way. Rosanna really is finessing the art of multitasking. Not only does she run Pygmalion but she has a full time job as a features reporter for a large news network. Incredible. I am delighted to say that Pygmalion candles are part of the pop-up I'm doing in Bruton at the moment and they are flying off the shelves. They are the perfect gift this Christmas. Please welcome to the podcast, the very dynamic Rosanna Philpott. Hosted on Acast. See acast.com/privacy for more information.

Among the latest data being presented at the American Society of Hematology Annual Meeting and Exposition, held December 7-10, 2024, in San Diego, California, were 3 abstracts that focused on patient preferences and treatment choices. Sikander Ailawadhi, MD, professor of medicine in the Division of Hematology/Oncology at the Mayo Clinic Florida was a coauthor on all 3 abstracts, covering patient preferences for Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma, survivorship burden and patient preferences affecting treatment choices in multiple myeloma, and race/ethnicity-specific sociodemographic and economic factors driving refusal of treatment in multiple myeloma.

Freight HHG has been on my radar for many years. With a paired back and tactile aesthetic, the acclaimed shop based in Lewes, Sussex understands the importance of materiality, beauty and the importance of creating atmospheric spaces. Launched in 2014, mother Helene, and daughter Adele, seem to have formed quite the duo with a wonderful mix of discernment, technical ability and the art of editing. Freight HHG - standing for Household Goods - have been a benchmark for me with Caro, as my team will have testified, so it was an absolutely privilege to chat with Adele - especially as she only gave birth 5 weeks ago to her son Kit. With a business model based in uk production, I was curious to hear how they have got on amongst the turbulent few years we've had - but also about the journey they've had growing a business that has confidence and an abundance of charm.Adele has such an eloquent way of talking shop. I am thrilled to say, I am selling their beautiful wares in my Pop Up - which is on now at The Space in Bruton until the 21st December - as well as on carosomerset.comPlease welcome Adele Adamczewski. Hosted on Acast. See acast.com/privacy for more information.

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Bruton Agammaglobulinemia⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Immunology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Zara Peters is the lovely face behind the name Queen of Bows. I don't know if you've noticed, but bows are featuring in quite a gib way at the moment and I am certain that it is something to do with Zara's bows because her's aren't just any bows. From giant, oversized bows to bows to put on cars, mantelpieces and front doors, Zara hand makes to order in a beautiful range of understated, natural fabrics. I am overjoyed to say that her bows, as well as her scrunchies will be at my pop-up starting this Saturday - at The Space in Bruton, please see my instagram profile for more details - Zara's bows just have this way of making everything feel festive and special.We have such a lovely conversation with rather a funny moment in the middle when we clear up a confusion we had around her thinking I called her a giant Elf - thank god we cleared that one up. As it's Christmas, I ask a few festive inspired questions which had a heartwarming turn this episode - I have been inspired talking to Zara about her take on Christmas and the traditions she invites her family to take part in.Lot's jingly bells to all of you and enjoy this festive episode. Hosted on Acast. See acast.com/privacy for more information.

The next few guests on the podcast are the founders of brands that I have invited to be a part of the Caro Pop-Up running for 2 weeks, starting on the 7th December in The Space in Bruton.Katie Leamon, was the first stationery brand I bought for Caro. Introduced to me by a mutual friend, I remember the eponymous marble collection selling out extremely fast. You can now find her greetings cards, wrap and notebooks in a number of luxury stores across the world including Harrods, Fortnum & Mason & Selfridges as well as many independent shops.We meet online and talk about the beginnings of her business - catapulted in 2010, after Liberty picked her up at one of their Open call days. We chat about how she's grown her brand and seen various iterations of what that looks like as well as where Katie Leamon is heading. We chat about the memorabilia that inspires her and how her designs organically evolve with her aesthetic but also her customers. I am excited to introduce her ReLove Christmas Collection to the pop-up, with traditionally illustrated fathers Christmas', reindeer and snow-topped cottages - it truly brings that nostalgic feeling we all love at this time of year. Hosted on Acast. See acast.com/privacy for more information.

Built airplane. Flew airplane. Crashed airplane. Met God. all set.Jim Bruton knows life. His past is marked by relentless curiosity and remarkable achievement. He was an African wilderness guide, Emmy Award-winning wildlife film director, aviator, adventurer, inventor of the satellite videophone, NBC News Middle East war correspondent, a husband, and a father.His passion - building and flying WWI-era aircraft - led him where he never imagined he'd go: a horrific crash that left him for dead. For one week, Jim Bruton hovered in the place that is not life and not death, a place he came to know as the In Between. He came back, and this is his report of what he has seen.Bruton takes us along for a by turns hair-raising and ultimately triumphant story of his coming to grips with what has happened to him. As he heals, his experiences in the In Between become more and more pressing. They download into his mind like rushing movie stills. His life of action turns internal. He uses all he knows - from quantum physics and battlefield memories to scenes of childhood and familial love - for a new deeper understanding of what it means to live.Jim Bruton, the man who fell from the sky, is not the same man who flew into it. And if you walk some of his journey with him, neither are you.About the author: Jim Bruton has lived a life many people dream of but few experience. As a little boy, he lived within an active imagination, including a love for wildlife filming, international travel, science fiction, and vintage aviation. In adulthood, he checked every one of those off his list with internationally recognized achievements, an Emmy for a National Geographic wildlife film, traveling to all seven continents, the Titanic, the North Pole, and Mt. Everest, shrinking a satellite TV truck into a backpack, and transmitting live video from places before impossible and building and flying historical reproduction aircraft from World War I and the early 1930s.For many, any one of these adventures resulted in a single lifetime achievement. For Jim, it was just the beginning, climaxing with the crash of his last aircraft and the near-death experience that followed.Jim is an Emmy award winning journalist and in this episode we talk about his about his Near Death Experience.From Jim's website;Generally, people who have had NDEs aren't trying to “sell” anything, other than perhaps a seminar, book or DVD.  We don't try to sell a new religion, because we left all that behind.  However, spirituality plays a pretty strong role in the experiences we share.  One of the strangest things I've noticed is that for those of us who had our NDEs as a result of some horrific accident, while in most cases the accident and its crazy circumstances would be the focus of any compelling story, an NDE negates that.Once an NDE enters the picture, you almost forget about the accident- it becomes the least important part of the story, next to the NDE.  My accident was amazing as accidents go, and I have an NDE friend who is only one of a handful in the world that she knows of who suffered and survived an internal decapitation.  But to NDE'ers, the circumstances that nearly, or do, kill us are just a footnote.  I'm sure that must be surprising, in some way.https://www.inbetweenproductions.com/https://www.amzn.com/dp/B098KQHX57 https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlife

Join host Dan Dworkis on The Emergency Mind Podcast as he interviews Vinton Bruton, Director of the Wilson Center for Leadership in the Public Interest at Hampden-Sydney College. Drawing on his diverse background as a Marine infantry officer, educator, and volunteer firefighter, Vinton shares insights on leadership development, character education, and the importance of experiential learning. Discover how principles from the military and outdoor adventure can be applied to teaching the next generation of leaders in various high-pressure environments, including emergency medicine. Don't miss this engaging discussion on developing effective, resilient leaders for tomorrow's challenges.

Built airplane. Flew airplane. Crashed airplane. Met God. all set.Jim Bruton knows life. His past is marked by relentless curiosity and remarkable achievement. He was an African wilderness guide, Emmy Award-winning wildlife film director, aviator, adventurer, inventor of the satellite videophone, NBC News Middle East war correspondent, a husband, and a father.His passion - building and flying WWI-era aircraft - led him where he never imagined he'd go: a horrific crash that left him for dead. For one week, Jim Bruton hovered in the place that is not life and not death, a place he came to know as the In Between. He came back, and this is his report of what he has seen.Bruton takes us along for a by turns hair-raising and ultimately triumphant story of his coming to grips with what has happened to him. As he heals, his experiences in the In Between become more and more pressing. They download into his mind like rushing movie stills. His life of action turns internal. He uses all he knows - from quantum physics and battlefield memories to scenes of childhood and familial love - for a new deeper understanding of what it means to live.Jim Bruton, the man who fell from the sky, is not the same man who flew into it. And if you walk some of his journey with him, neither are you.About the author: Jim Bruton has lived a life many people dream of but few experience. As a little boy, he lived within an active imagination, including a love for wildlife filming, international travel, science fiction, and vintage aviation. In adulthood, he checked every one of those off his list with internationally recognized achievements, an Emmy for a National Geographic wildlife film, traveling to all seven continents, the Titanic, the North Pole, and Mt. Everest, shrinking a satellite TV truck into a backpack, and transmitting live video from places before impossible and building and flying historical reproduction aircraft from World War I and the early 1930s.For many, any one of these adventures resulted in a single lifetime achievement. For Jim, it was just the beginning, climaxing with the crash of his last aircraft and the near-death experience that followed.Jim is an Emmy award winning journalist and in this episode we talk about his about his Near Death Experience.From Jim's website;Generally, people who have had NDEs aren't trying to “sell” anything, other than perhaps a seminar, book or DVD.  We don't try to sell a new religion, because we left all that behind.  However, spirituality plays a pretty strong role in the experiences we share.  One of the strangest things I've noticed is that for those of us who had our NDEs as a result of some horrific accident, while in most cases the accident and its crazy circumstances would be the focus of any compelling story, an NDE negates that.Once an NDE enters the picture, you almost forget about the accident- it becomes the least important part of the story, next to the NDE.  My accident was amazing as accidents go, and I have an NDE friend who is only one of a handful in the world that she knows of who suffered and survived an internal decapitation.  But to NDE'ers, the circumstances that nearly, or do, kill us are just a footnote.  I'm sure that must be surprising, in some way.https://www.inbetweenproductions.com/https://www.amzn.com/dp/B098KQHX57/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlife

In this episode of VisionCraft Presents Coffee in the Green Room, host Deneen White has a deeply moving conversation with Lori Bruton, a woman who overcame profound personal struggles and emerged stronger and more determined than ever to help others break free from toxic relationships. Lori shares her personal journey, beginning with a seemingly perfect life that took unexpected turns, leading her through hardship, a painful toxic relationship, and ultimately a transformation that inspired her to empower others.Lori's story is one of hope and resilience. After experiencing a major life breakdown, she found herself in a relationship that drained her sense of self. It was only through the support of friends, mentors, and her own determination that she was able to reclaim her life. Lori also dives into her work as a writer, discussing her first book, Whole to Whole: Journey to Hope and Transformation, a testament to her journey toward self-discovery and healing. With honesty, she shares her defining moments, from a pivotal experience on stage with renowned transformation coach Gary Coxe, to her courageous steps toward building a new life.Tune in to this inspiring conversation as Lori discusses how she went from merely surviving to thriving. Whether you're overcoming your own challenges or simply need a dose of hope, Lori's words are sure to resonate. Follow Lori's journey and find out more about her work by visiting LoriBruton.com.VISION CRAFT COUSEhttps://www.visioncraftcourse.com/REGISTER FOR OUR NEXT ONLINE, NO-COST AUDITIONhttps://www.ammsociety.com/CHECK OUT VIP IGNITE'S FREE MODEL AND ACTOR BOOTCAMPhttps://vipignitesummit.comFOR MORE INFORMATION ABOUT VIP IGNITE https://vipignitelive.com/CHECK US OUT ON FACEBOOK:https://www.facebook.com/vipigniteliveCHECK US OUT ON INSTAGRAMhttps://www.instagram.com/vipigniteCHECK US OUT ON TWITTER:https://www.twitter.com/vipigniteCHECK OUT THE HOLLYWOOD MINDSET WEBSITE HERE:https://www.hollywoodmindset.comCHECK OUT THE COFFEE IN THE GREEN ROOM PODCAST HERE:https://www.coffeeinthegreenroom.comCHECK OUT THE VIP IGNITE LIVE PODCAST HERE: https://www.vipignitelivepodcast.comCHECK OUT WHAT PEOPLE ARE SAYING HERE:https://www.youtube.com/playlist?list=PLLzqEyOG...

Mud Australia is a brand known for their timeless porcelain homewares, minimalist aesthetic and their extensive colour palette. Since opening their first store in 2007, there are now 12 MUD stores all over the world. I am delighted to invite founder Shelley Simpson onto the podcast today. As a shopkeeper of just one little shop in Bruton, it was a privileged to chat to Shelley about how she grew Mud from making small runs of homewares to mass producing for a fleet of stores. From the conversation I had with Shelley, it is clear that she is not only a smart businesswoman, but that she has a fundamental ambition to work with people and on the ground, where the action is. We chatted about her personal experience in retailed aged 40, and how that inspired the ethos at Mud, and the different ways in which various cultures use her tableware depending on what they eat and the way they eat. We also talk about the Shelley Simpson Ceramic Prize held by Mud Australia every year - and this years winner, Alfred Lowe. I completely fell in love with Alfred's pieces when I saw them - and more so when I read the inspiration behind them. He describes the importance of their bright colours and fun appearance in holding their presence in a room ‘ a presence that rejects expectations, ignores preconceptions and embraces a provocative sense of rebellion.' It is initiatives like the ceramic prize that make Shelley Simpson a true inspiration. Hosted on Acast. See acast.com/privacy for more information.

In this episode, we meet Jim Bruton, a man who has traveled the world, chased storms, reported from war zones, and worked in realms many would only dream of. But in a twist of fate, a plane crash brought him somewhere altogether unexpected—the in-between. From this surreal vantage point, Jim experienced a near-death journey that went beyond the usual light and tunnel, plunging him into a vast landscape of choices, probabilities, and life's potential futures.Jim's adventure starts with a daring passion for aviation. In 2016, while testing his homemade plane, his engine cut out mid-air, sending him into a violent crash. That moment of impact shattered not only his body but his concept of reality. In the haze of unconsciousness, Jim describes suddenly “teleporting” to what felt like a post-apocalyptic cityscape, where a sense of calm enveloped him. There was no fear, just the quiet understanding that he was somewhere beyond the ordinary—standing in what he would come to call “the eternity of a single moment.”As Jim looked around, he noticed a towering, latticed egg filled with gears, each one delicately hovering in space. The gears represented choices, futures, and possibilities, he explained, and each one could be felt rather than seen. Some gears brought a sense of peace; others, when touched, emitted a wave of nausea or pain, signaling a choice that could lead to suffering. “It's the process of becoming,” a disembodied voice told him, urging Jim to engage with his own fate as he would a living puzzle.In this vast in-between, Jim began removing the “painful” gears, choices that would have led him to spiritual dead-ends. One gear hinted at a lottery win, yet the pull of its danger told Jim that path would derail his journey, leading him away from his spiritual progress. His reflex was to let it go, casting the gear aside as it dissolved into the space around him. "For those who make poor use of their choices, offering fewer possibilities could be called Mercy," the voice added, an insight that profoundly shifted Jim's understanding of free will and destiny.This experience wasn't passive; Jim was in control, an active participant in navigating the paths his life could take. His choices in that space weren't just about personal gain—they were about finding the right road to spiritual evolution, learning to let go of what no longer served him. The voice urged him to remember that each decision has unseen impacts, rippling through time and space, shaping not only his life but all connected to him.After what seemed like an eternity, Jim was directed back to the waking world with a final message: “Pay attention to your relationships.” This wisdom stayed with him, offering a new perspective on the bonds that shape us. Since his experience, Jim finds that people are drawn to him in a different way, responding to a quiet, unspoken depth within him. His near-death journey left him with a gentle detachment, one that allows him to see beyond the surface and connect more authentically with others.Jim's return to life wasn't just about survival; it was about living with intentional awareness, treating each interaction as an opportunity for growth and understanding. His journey through the in-between was a reminder that we are not here to amass things or fulfill ambitions but to evolve spiritually, to learn, and, ultimately, to let go.SPIRITUAL TAKEAWAYSEmbrace Your Choices with Reverence: Jim's journey reminds us that each choice shapes not just our future but our spiritual trajectory. Trusting the "grand design" helps us make decisions aligned with a higher path.Life as a Mosaic of Connections: Every relationship, Jim shares, carries an unseen purpose. By nurturing these connections and living authentically, we align closer to our spiritual essence.Detach and Let Go: The true power, Jim says, lies in the art of letting go. When we release attachment, we allow life to unfold organically, connecting us to our higher purpose.Please enjoy my conversation with Jim Bruton.Become a supporter of this podcast: https://www.spreaker.com/podcast/next-level-soul-podcast-with-alex-ferrari--4858435/support.

Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.

Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/BTKInhibitorsMCL24).

My first guest for this series is a goodun. It is Tom Calver of Westcombe Dairy - and is probably the most entrepreneurial person I know. Every time I see him he's thinking up or in the middle of executing some amazing idea. Westcombe cheese are regularly name checked on the menu's of great restaurants which is testament to the flavour and quality of the cheese they produce. Tom has taken a family business which is steeped in heritage and made a brand that is about community. He is humble, passionate and also generous - when I arrived to record the podcast and his colleague Corina had surprised me with an amazing spread of their cheese and meat which you'll hear me savouring in a minute with lots of mmm's and ahhh's. Westcombe Dairy is not only a regarded name for cheese, and now charcuterie, but it is also known for being a destination. In a small village near Bruton, Westcombe is now the home to Brickell's ice cream, Landrace mill and now Woodshedding tap room so you can visit and have a fresh beer. Hosted on Acast. See acast.com/privacy for more information.

Send us a textLisa Bruton is a speaker, podcaster, and founder and director of Arise Sanctuary, an organisation that has offered over 45 luxury boutique retreats for women in locations around the world. She is passionate about creating spaces for others to slow down, connect to God and hear His voice.Lisa has spoken at conferences and churches throughout Australia and overseas, where she openly shares her heart, funny mishaps, lessons and revelations. Lisa is a wife to Matty and mum to two young girls, Aria and Coco. In her spare time, she loves to surf and travel with herfamily.Support the showwww.greaterthingsinternational.com

In this episode of The Run the Riot Podcast, David chats with Alex Bruton, a newly dedicated ultrarunner and participant in the Run the Riot coaching program. Fresh off achieving a monumental goal—running 50 kilometers for his 50th birthday—Alex shares the incredible journey of preparing for his big challenge. Throughout the conversation, Alex and David discuss how ultrarunning, like Alex's personal "moonshot" projects, pushes the boundaries of mental and physical endurance. Tune in to hear Alex's reflections on the importance of believing in yourself, embracing the grit, and finding the joy in every milestone. Alex also dives into how this ultrarunning journey parallels his work in innovation, especially with his Moonshot Opportunity System (Moonshot OS), helping individuals achieve massive goals. They also touch on his heartfelt cause: raising funds for Give a Mile, a charity that provides flights for families to reunite during times of terminal illness. Show notes here: http://www.theriot.run/alexb If you're ready to push your limits and take on new challenges, check out our coaching page at Run the Riot Coaching. Hashtags: #runtheriot #ultrarunning #ultrarunner #trailrunning #moonshot #trailrunner #50kmrun

Dr. Rick Perea and Super Bowl 50 Champion Dr. David Bruton on his football career and journey to becoming a physical therapist following his retirement from the NFL.

Welcome to Supreme Court Opinions. In this episode, you'll hear the Court's opinion in Samia v United States. In this case, the court considered this issue: Does admitting a codefendant's redacted out-of-court confession that immediately inculpates a defendant based on context violate the Confrontation Clause of the Sixth Amendment? The case was decided on June 23, 2023. The Supreme Court held that the admission of a non-testifying codefendant's confession did not violate the Sixth Amendment's Confrontation Clause where the confession as modified did not directly inculpate the defendant but used the descriptor “other person” and the jury was instructed to consider the confession only as to the codefendant. Justice Clarence Thomas authored the majority opinion of the Court. Historically, a non-testifying codefendant's confession was permissible if the jury was instructed not to consider it against the nonconfessing defendant. The Court in Bruton v United States, recognized an exception to that general rule, holding “that a defendant is deprived of his Sixth Amendment right of confrontation when the facially incriminating confession of a non-testifying codefendant is introduced at their joint trial,” even with a proper instruction. However, the Court established certain outer limits on the Bruton rule. For example, in Richardson v Marsh, the Court did not extend the rule to confessions that do not name the defendant, although, in Gray v Maryland, the Court clarified that some redacted confessions might still be directly accusatory if the redaction is evident. Here, the confession was redacted to avoid naming the defendant, aligning with the Bruton rule and differing from the confession in Gray. The Court declined to further extend the Bruton rule, reasoning that its extension would disrupt historical practices and necessitate extensive pretrial hearings, potentially leading to mandatory severance in joint trials when introducing a non-testifying codefendant's confession. This would undermine the role of joint trials and the significance of confessions in the legal system. Justice Amy Coney Barrett joined the majority opinion except the historical discussion, which, in her separate concurrence, she argues is beside the point. She would limit consideration to the meaning of the Confrontation Clause at the time of the founding and reach the same conclusion. Justice Elena Kagan authored a dissenting opinion, in which Justices Sonia Sotomayor and Ketanji Brown Jackson joined, arguing that the non-testifying codefendant's confession in this case inculpated the defendant in the same way that the Court recognized it would in other cases. Justice Kagan criticized the majority for “permitting an end-run around the Court's precedent and undermining a vital constitutional protection for the accused.” The opinion is presented here in its entirety, but with citations omitted. If you appreciate this episode, please subscribe. Thank you.  --- Support this podcast: https://podcasters.spotify.com/pod/show/scotus-opinions/support

Today we have the much loved Anna Murray on the podcast. Anna is best known for co-founding Patternity, a creative agency pioneering change through the use pattern set up back in 2004. We sit down at my kitchen table and talk about a lot. About how she came to live in Bruton and set up Spirals, a space a concept store in Bruton. We talk about the process of creativity and what community brings to our lives as well as spirituality and connection. This is probably the most uncut episode I've done and that's because there's just so much flow and joy with Anna - She is one of the most reflective and open people I know. Happy listening. Hosted on Acast. See acast.com/privacy for more information.

It is a pleasure to welcome Caroline Strecker to the podcast today. Founder of repurposed leatherwork brand, Caroline is a true champion of sustainable style and slow fashion. Each of her iconic bags is handmade which is no mean fete when you see the quality of the bridal leather she works with. I have been lucky enough to see her brand grow from an idea, into a community and now intro a retail space and studio in Bruton which is incredibly beautiful. We talk about her story to getting here, the circular economy, finding sustainable growth in retail and the process behind her unique designs. She's one of a kind and definitely one to listen too….. Hosted on Acast. See acast.com/privacy for more information.

At the 2024 European Hematology Association (EHA) Congress, CancerNetwork® spoke with a variety of experts in the hematologic oncology space about optimizing outcomes across different patient populations and subgroups based on updated research they presented at the meeting.  Manali Kamdar, MD, an associate professor of medicine-hematology and clinical director of Lymphoma Services at the University of Colorado Anschutz Medical Campus, in Colorado, spoke about data from the phase 1 TRANSCEND NHL 001 trial (NCT02631044) supporting the use of lisocabtagene maraleucel (liso-cel; Breyanzi) in earlier lines of therapy for patients with relapsed/refractory mantle cell lymphoma (MCL).1  Specifically, Kamdar highlighted how research should continue to focus on the potential utility of liso-cel in MCL subgroups such as those with TP53 mutations or blastoid morphology. Additionally, she stated that liso-cel may need to be further tested in earlier lines of therapy for patients with diffuse large B-cell lymphoma, including those with double-hit lymphoma. Michael R. Grunwald, MD, chief of the Leukemia Division and director of the Transplantation and Cellular Therapy Program at Atrium Health's Levine Cancer Institute, in North Carolina, discussed findings from the Prospective Observational Study of Patients With Polycythemia Vera (PV) in US Clinical Practices Trial (REVEAL) exploring risk factors for disease progression in patients with polycythemia vera (PV).2 According to Grunwald, a history of thromboembolic events, elevated white blood cell counts, and higher variant allele frequencies may contribute to a patient's likelihood of experiencing progression to myelofibrosis or acute myeloid leukemia (AML). Additionally, he highlighted ongoing research into the potential molecular factors that may prognosticate disease transformation in PV among a small cohort of patients enrolled on the REVEAL trial.3 Harry P. Erba, MD, PhD, a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy and the director of the Leukemia Program and Phase I Development in Hematologic Malignancies at Duke Cancer Institute, in North Carolina, discussed the clinical implications of data from the phase 3 QuANTUM-First study (NCT02668653).4  Specifically, findings demonstrated that continuation therapy with quizartinib (Vanflyta) elicited a more pronounced survival benefit vs placebo in patients with newly diagnosed FLT3-ITD–positive AML who did not undergo allogeneic hematopoietic stem cell transplant (allo-HSCT). However, Erba noted that survival outcomes were not significantly different in the quizartinib and placebo arms among patients who received allo-HSCT. References 1.        Palomba ML, Siddiqi T, Gordon LI, et al. Subgroup analyses in patients with R/R MCL treated with lisocabtagene maraleucel by prior lines of therapy and response to Bruton tyrosine kinase inhibitor from the TRANSCEND NHL 001 MCL cohort. Presented at the European Hematology Association (EHA) 2024 Congress; Madrid, Spain; June 13-16, 2024. P1126. 2.        Grunwald M, Zwicker J, Gerds A, et al. A real-world evaluation of risk factors for disease progression in patients with polycythemia vera (PV) enrolled in REVEAL. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract P1047. 3.        Crowgey E, Timmers C, Xue Z, et al. Analysis of molecular mechanisms and predictive biomarkers of disease transformation in polycythemia vera. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract S217. 4.        Sekeres MA, Erba H, Montesinos P, et al. QuANTUM-First: efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation therapy. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract S142.

The Ice Guys NHL Hockey betting show presented by Boston Hemp Inc. for Saturday, June 15 as Ian Cameron, Alex B. Smith and special guest former pro hockey player Chris Bruton (Twitter/X: @chrisbruton1987) preview and analyze Game 4 of the Stanley Cup Final between the Florida Panthers and Edmonton Oilers (sides, totals, props) from a betting perspective Follow The Ice Guys on Twitter/X Ian Cameron (Twitter/X: @bobanobets) Alex B. Smith (Twitter/X: @axsmithsports) Follow The Ice Guys official show Twitter The Ice Guys (Twitter/X: @The_IceGuys) Sign up and subscribe for just $10 per month to become an Ice Guys Patreon member at http://www.patreon.com/iceguys to get all sides, totals and player props every single day, bonus content, goalie and totals charts, Players Suite Interviews, Patreon Exclusive Ice Guys Live Betcasts and more! Be sure to check out the quality products from our proud sponsor Boston Hemp Inc. today and use Promo Code 'ICEGUYS' to save 20% off All Orders at https://bostonhempinc.com/

 To Support the Channel:Patreon  https://www.patreon.com/AskZacTip jar:  https://paypal.me/AskZacVenmo @AskZac Or check out my store for merch  - https://my-store-be0243.creator-spring.com/Today we look back at Delbert McClinton's 1989 Alligator Records release, Live From Austin. The year it was released, I was 16 and a drummer friend gave me this album on cassette, and I completely wore it out. Having not been exposed to much besides top-40 of the 1980s, and the contemporary gospel music of the day, The Texas Roadhouse music of McClinton was a revelation with its big, sweaty horns, incredibly tight rhythm section, and fine harp work. The band also featured the guitar work of David Millsap and Stephen Bruton, who brilliantly complemented each other with both their tones and parts. In a conversation with another Delbert veteran, James Pennebaker, I was clued into the fact that Bruton was sitting in with the band for the Austin City Limits TV taping that was also used as the audio for the "Live From Austin" album. Besides diving in on this wonderful album, we also take a look at the influence of the late great Stephen Bruton.Amazon Link to albumhttps://amzn.to/3Vg7fW2Spotifyhttps://open.spotify.com/album/3G0J7CgCqslFZf9XMSimIj?si=zTuTt-_qRKWqIOwfToJ-8QBruton playlisthttps://open.spotify.com/playlist/6MSreKA4PmWffPtJ1wJoZ3?si=96fc6ab90856495dStrings: D'Addario NYXL 95-44https://amzn.to/41rnl0V2023 Headstrong Lil' King with 12" Eminence GA-SC64 speakerhttps://headstrongamps.com/lil-king-amp#askzac #stephenbruton #delbertmcclinton Support the Show.

BUFFALO, NY- June 4, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 3, 2024, entitled, “Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.” In this new perspective, researchers Jai N. Patel, Jai Singh, and Nilanjan Ghosh from Atrium Health discuss Ibrutinib — the first Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of patients with chronic lymphocytic leukemia (CLL). “While producing durable responses and prolonging survival, roughly 20–25% of patients experience dose limiting side effects, mostly consisting of cardiovascular toxicities like severe hypertension and atrial fibrillation.” While clinical predictors of BTK inhibitor-related cardiotoxicity have been proposed and may aid in risk stratification, there is no routine risk model used in clinical practice today to identify patients at highest risk. A recent study investigating genetic predictors of ibrutinib-related cardiotoxicity found that single nucleotide polymorphisms in KCNQ1 and GATA4 were significantly associated with cardiotoxic events. If replicated in larger studies, these biomarkers may improve risk stratification in combination with clinical factors. “A clinicogenomic risk model may aid in identifying patients at highest risk of developing BTK inhibitor-related cardiotoxicity in which further risk mitigation strategies may be explored.” DOI - https://doi.org/10.18632/oncotarget.28589 Correspondence to - Nilanjan Ghosh - nilanjan.ghosh@atriumhealth.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28589 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, BTK inhibitor, cardiotoxicity, biomarkers, risk, genetics About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Xavier Montalban, MD, PhD - Multiple Sclerosis and Bruton's Tyrosine Kinase Inhibitors: Therapeutic Potential Beyond Biologics?

Keith Bruton returns to OutWithDan to chat about our favorite Hit Man with OCD. Again Bruton gives us so many reasons to love Patrick Callen. Patrick's love for Olivia conflicts with his profession and we see how he struggles with making life changes at the same time being caught up in so many dramas of his own or others' making. www.outwithdan.com www.keithbruton.com

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Daniel Ontaneda, MD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, sat down to discuss the recently concluded Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. Ontaneda, program committee vice-chair of the meeting, provided insight on a number of notable sessions and discussions that highlighted the recent advances in the MS field. In addition, he talked about the need to innovate clinical trials, ways to tackle progressive MS, and whether drug trials are truly assessing patients at the right time points. Furthermore, he discussed multi-stage trials, the potential role of Bruton tyrosine kinase (BTK) inhibitors, and how this year's meeting differs from previous ones.  Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page. Episode Breakdown: 1:05 – Overviewing sessions from ACTRIMS Forum 13:10 – Innovating clinical trial design 16:15 – 2023 ACTRIMS vs 2024 ACTRIMS 20:20 – Neurology News Minute 23:30 – Testing combination approaches for progressive MS 26:45 – The impact of timing therapeutic interventions  This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA AdComm to Review Investigational Alzheimer Agent Donanemab and Phase 3 Results Amylyx Mulls Over Pulling AMX0035 Following Disappointing Phase 3 PHOENIX Findings FDA Issues Complete Response Letter for Long-Acting Form of Glatiramer Acetate for Relapsing Multiple Sclerosis Phase 2 PROCEED Trial of PACAP-Targeting Antibody Lu AG09222 in Migraine Announced Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

In this episode, me and my friend Dylan Bruton of Clutch Points talk some of the biggest free agency signings of what's been a chaotic NFL Offseason. From Saquon Barkley to the Philadelphia Eagles (1:12), Derrick Henry to the Baltimore Ravens, & Russell Wilson signing the veteran minimum to join the Pittsburgh Steelers. We get into it all on this great episode collaboration. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dj-hamilton5/message

The coelacanth was believed to have gone extinct about 66 million years ago, until one was spotted in South Africa in 1938. Naturalist and museum curator Marjorie Courtenay-Latimer played a key part in that event. Research: Ashworth, Willam B. Jr. “Scientist of the Day – Marjorie Courtenay-Latimer.” Linda Hall Library. 2/24/2020. https://www.lindahall.org/about/news/scientist-of-the-day/marjorie-courtenay-latimer/ Bruton, Mike. “Curator and Crusader: The Life and Work of Marjorie Courtenay-Latimer.” Pinetown Printers, 2019. Courtenay-Latimer, M. “My Story of the First Coelacanth.” Occasional Papers of the California Academy of Sciences. No. 134. 12/22/1979. https://www.biodiversitylibrary.org/page/15956893#page/18/mode/1up Courtenay-Latimer, Marjorie. “Reminiscences of the Discovery of the Coelacanth, Latimeria chalumnae.” Interdisciplinary Journal of the International Society of Cryptozoology. Vol. 8. 1989. Hatchuel, Martin. “The Coelacanth.” Knysna Museums. https://www.knysnamuseums.co.za/pages/the-coelacanth/ Jewett, Susan L. “Marjorie Courtenay-Latimer: More than the Coelacanth!” Division of Fishes, Smithsonian Institution. Schramm, Sally. “Marjorie Eileen Doris Courtenay-Latimer: Beyond the Coelacanth.” Biodiversity Heritage Library Blog. https://blog.biodiversitylibrary.org/2019/03/marjorie-eileen-doris-courtenay-latimer.html Smith, Anthony. “Marjorie Courtenay-Latimer.” The Guardian. 5/20/2004. https://www.theguardian.com/news/2004/may/21/guardianobituaries Smith, J.L.B. “The Living Cœlacanthid Fish from South Africa.” Nature 143, 748–750 (1939). https://doi.org/10.1038/143748a0 Smith, J.L.B. “The Search Beneath the Sea: The Story of the Coelacanth.” New York. Holt. 1956. Smith, J.L.B. Living Fish of Mesozoic Type.” Nature 143, 455–456 (1939). https://doi.org/10.1038/143455a0 The Coelacanth : the Journal of the Border Historical Society. Vol. 42 No. 1 (2004). https://journal.ru.ac.za/index.php/Coelacanth/issue/view/143 Tyson, Peter. “Moment of Discovery.” PBS Nova. https://www.pbs.org/wgbh/nova/fish/letters.html Weinberg, Samantha. “A Fish Caught in Time: the Search for the Coelacanth.” New York : HarperCollins Publishers. 2001. Yanes, Javier. “The Woman Who Brought a Fish Back From the Dead.” BBVA Open Mind. 2/17/2023. https://www.bbvaopenmind.com/en/science/leading-figures/marjorie-courtenay-latimer-fossil-fish-coelacanth/ See omnystudio.com/listener for privacy information.

Lisa Bruton: Fully Alive — Fully Found Lisa shares with Lana and Courtney some powerful personal testimonies that show how God relentlessly pursues us. The heart of her story is knowing who the Father is and how much He tenderly loves us. With a focus on Him, we can be free to be authentically ourselves. Free to make mistakes, free to be imperfect — because He doesn't wait for us to get it all together before He uses us. Even when we feel God is far away, He is always there: and there is power in a simple prayer of ‘Help.' If we look for Him everywhere, we will find Him.

American author Robert Bruton takes us through his Master's thesis on the role of climate change and plague in the decline of Roman fortunes in the 6th century.He is also writing a trilogy of historical fiction novels about the life of Belisarius. Find out more about Robert and his work here. Hosted on Acast. See acast.com/privacy for more information.

It's time once again to talk dollars and cents (and sense..) as Kelley Earnhardt Miller is back in the Bojangles Studio for the second edition of the Business of Motorsports. On this episode, she is joined by co-host Mike Davis and the President/CEO of Speedways Motorsports Inc., Marcus Smith. While Marcus has been a recurring guest on the Dale Jr. Download, this interview dives more into the nuts and bolts of how speedways operate and his business philosophy.Marcus discussed his path up the ladder at SMI and imparted advice he received from his father Bruton and former President of Charlotte Motor Speedway Humpy Wheeler. He also chats about the research that goes into keeping racing fans happy, the process of making the NASCAR schedule, track reconfigurations, and the speedways' perspective in the ongoing negotiations surrounding the next NASCAR broadcasting deal. Listeners can expect to hear some updates on the NASCAR All-Star weekend at North Wilkesboro and what the future may hold for the legendary track. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

It's time once again to talk dollars and cents (and sense..) as Kelley Earnhardt Miller is back in the Bojangles Studio for the second edition of the Business of Motorsports. On this episode, she is joined by co-host Mike Davis and the President/CEO of Speedways Motorsports Inc., Marcus Smith. While Marcus has been a recurring guest on the Dale Jr. Download, this interview dives more into the nuts and bolts of how speedways operate and his business philosophy. Marcus discussed his path up the ladder at SMI and imparted advice he received from his father Bruton and former President of Charlotte Motor Speedway Humpy Wheeler. He also chats about the research that goes into keeping racing fans happy, the process of making the NASCAR schedule, track reconfigurations, and the speedways' perspective in the ongoing negotiations surrounding the next NASCAR broadcasting deal. Listeners can expect to hear some updates on the NASCAR All-Star weekend at North Wilkesboro and what the future may hold for the legendary track. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices